Innovation Drives Pharmaceutical Industry Growth, States GBI Research in Its New Report Recently Added at MarketPublishers.com
20 Jul 2016 • by Natalie Aster
LONDON – Innovation, especially the development and introduction of novel products, is nowadays recognised as a crucial element of the global pharmaceutical industry development. The world’s pharmaceutical market is characterised as a highly research-intensive one. This market is strongly dependent on a high level of R&D investments and also on a strong product pipeline to maintain positive growth and, furthermore, ensure long-term revenue generation. Without successful innovations, which can be widely defined as launches of new therapeutic molecules and cost-effective treatment options, the global pharmaceutical industry will likely experience a substantial long-term decrease in revenues.
During the recent decades, additionally to a rise in the annual number of novel chemical entity approvals by the FDA, the proportion and total number of these approvals that were first-in-class at the time of approval have increased as well.
GBI Research’s cutting-edge research publication, “Innovation Tracking Factbook 2016 - An Assessment of the Pharmaceutical Pipeline”, presents a detailed overview of the 20,756 products presently available in the global pharmaceutical industry pipeline, it contains data on products on various stages of development (from the discovery stage up to pre-registration stage) and also split into various key indications and therapy areas. The report also benchmarks the pipeline against its size across all segments in 2015 and assesses the level of first-in-class innovation. Moreover, a granular contextual analysis of the major drivers of the pharmaceutical industry pipeline is offered in the report along with trustworthy info on companies active in the pharmaceutical market. A major focus of this study is made on analysis of the development of innovative drugs, specifically first-in-class innovation.
More reports by GBI Research are provided at this page.